EXECUTIVE ENGAGEMENTS
POOL
3853
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
694
Interactions with Platform & by Email
PARTICIPANTS
116
Unique # Participated
VALIDATIONS
33
Responses Validated*
COMPANIES
16
Responses Validated*
* Login for a full stack data experience
DATE
OCT 2022
TABLES
202
PAGES
262
EDITION
6
PRICE
USD 4950
CODE
MCP10866
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global Cancer Supportive Care Market to Reach $26 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Cancer Supportive Care estimated at US$22.8 Billion in the year 2020, is projected to reach a revised size of US$26 Billion by 2027, growing at a CAGR of 1.9% over the analysis period 2020-2027. Opioids, one of the segments analyzed in the report, is projected to record a 2.1% CAGR and reach US$9.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the G-CSFs segment is readjusted to a revised 1.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $6.7 Billion, While China is Forecast to Grow at 1.5% CAGR
The Cancer Supportive Care market in the U.S. is estimated at US$6.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2027 trailing a CAGR of 1.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.8% and 1.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.NSAIDs Segment to Record 1.7% CAGR
In the global NSAIDs segment, USA, Canada, Japan, China and Europe will drive the 1.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3 Billion in the year 2020 will reach a projected size of US$3.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
SELECT PLAYERS
Amgen, Inc.; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Helsinn Healthcare SA; Heron Therapeutics, Inc.; Johnson & Johnson; Kyowa Hakko Kirin Co., Ltd.; Merck & Co., Inc.; Novartis AG; Tesaro, Inc.; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» Therapeutic Class (Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs, Antiemetics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Cancer Supportive Care – Global Key Competitors Percentage Market Share in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for G-CSFs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for ESAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Cancer Supportive Care Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| JAPAN |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| CHINA |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| EUROPE |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| FRANCE |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| GERMANY |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com